PASSReviewer 1· 100% conf
The paper is transparent: methods are complete, trial is registered, reporting guideline is referenced, all outcomes are reported, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.
Evidence
direct quote[Abstract]
“Clinicaltrials.gov registration: NCT06142383 (https://clinicaltrials.gov/study/NCT06142383) .”direct quote[Discussion, paragraph 5]
“These findings need to be considered in light of their limitations. Because the trial was terminated early for safety concerns, it lacked sufficient power to adequately test the primary biomarker hypothesis, and the data presented need to be considered hypothesis-generating.”direct quote[Acknowledgements and Competing interests]
“The trial was funded by Novartis.”PASSReviewer 2· 95% conf
The paper is well-reported with a registered trial, detailed methods, and transparent discussion of limitations and funding.
Evidence
paraphrase[Abstract, Methods]
“Clinicaltrials.gov registration: NCT06142383 (https://clinicaltrials.gov/study/NCT06142383).”direct quote[Discussion, paragraph 5]
“Because the trial was terminated early for safety concerns, it lacked sufficient power to adequately test the primary biomarker hypothesis, and the data presented need to be considered hypothesis-generating.”direct quote[Acknowledgements, Competing interests]
“The trial was funded by Novartis.”PASSReviewer 3· 85% conf
The manuscript is transparent and complete: trial registration, detailed methods, full outcome reporting including negative results, limitations, and funding/COI are all present.
Evidence
direct quote[Abstract]
“Clinicaltrials.gov registration: NCT06142383 (https://clinicaltrials.gov/study/NCT06142383)”direct quote[Discussion]
“Because the trial was terminated early for safety concerns, it lacked sufficient power to adequately test the primary biomarker hypothesis, and the data presented need to be considered hypothesis-generating.”direct quote[Acknowledgements / Competing interests]
“The trial was funded by Novartis.”